Idorsia Ltd (IDRSF) TRYVIO Investor Q&A Webcast and Conference Call

Operator

Good day and thank you for standing by. Welcome to Idorsia’s TRYVIO Investor Q&A Webcast and Conference Call.

[Operator Instructions]

Please be advised that today’s conference is being recorded. I would now like to hand the conference over to Idorsia’s Chief Executive Officer, Srishti Gupta. Please go ahead.

Srishti Gupta
CEO & Executive Director

Thank you, Nadia. Good afternoon and good morning, everyone, and welcome to our webcast to discuss TRYVIO and its role in the treatment landscape for difficult-to-control hypertension. After decades of limited progress in hypertension research, we are now entering an exciting new era, led by TRYVIO, the first innovation in hypertension in over 2 decades. It is the first and only hypertension therapy to target the endothelin pathway.

Ahead of the European Society of Cardiology, ESC, meeting, we published an on-demand investor webcast, sharing our perspectives on TRYVIO’s ability to address a significant unmet need and difficult-to-control hypertension. Since then, we’ve engaged with leading hypertension experts at both ESC and the American Heart Association’s Hypertension Scientific session. We’ve also met with many of you in the investor community as the back-to-school season kicks off in the U.S.

Today, we’ll address the key questions we’ve been hearing in those discussions and then open the lines to take your questions on TRYVIO. Joining me are Martine Clozel, our Chief Scientific Officer and a recognized leader in the endothelin system; Alessandro Maresta, Global Medical Affairs Therapeutic Area Head